How much does a box of Sotoraxibu cost in 2024?

Sotorasib is an inhibitor that targets the KRAS G12C mutation and is specifically designed to treat patients with advanced non-small cell lung cancer (NSCLC) carrying the KRAS G12C mutation. KRAS G12C mutation is one of the common and difficult-to-treat gene mutations in lung cancer. Due to the unique structure of KRAS protein, there has been a long lack of effective targeted drugs. By selectively binding to the KRAS G12C mutated protein, inhibiting its activity and preventing the proliferation and spread of cancer cells, sotoracib has become the world's first approved KRAS G12C targeted therapy drug. Clinical trials have confirmed that sotorasiib has a significant effect on KRAS G12C mutation-positive patients, especially for patients who have relapsed after receiving multiple lines of therapy. This drug provides a new treatment option.

In China, sotorasibu is not currently on the market, patients cannot purchase this drug through formal channels, and its medical insurance reimbursement issues have not yet been addressed. Therefore, if domestic patients need medication, they usually choose to purchase drugs through overseas channels. At present, the original drug of sotorasibu has been launched in foreign countries such as Europe and Hong Kong, China, but the price is relatively expensive. According to market information, the selling price of the original drug of sotorasibu in these areas is usually in the range of tens of thousands of yuan, and the price per box is relatively high, which puts great pressure on the financial conditions of patients' families.

In addition to the original drug, some countries and regions have launched generic drugs of sotorasibu, among which the price of generic drugs in Laos is the most affordable. For example, the current price of the generic drug Sotorasibu produced by Lucius and Big Bear Pharmaceuticals in Laos is about more than 1,000 yuan to more than 2,000 yuan per box. These generic drugs have the same ingredients and effects as the original drugs, but at significantly lower prices, making them suitable for patients with long-term treatment needs and significantly reducing their economic burden.

In the future, sotolaxib is expected to be officially launched in China. If it can be included in the medical insurance directory, it will further reduce the cost of medication for patients and benefit more patients.